Dallah Healthcare CoSAU:4004 -0.18%91 ROE % is 8.26% as of Mar. 2026, which is 42% below its 10-year median of 14.13. GuruFocus rates SAU:4004 with a GF Score™ of 91/100 and a GF Value™ of ﷼205.01 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 626 Healthcare Providers & Services companies, Dallah Healthcare Co ranks better than 67.09% on this metric.
The historical rank and industry rank for Dallah Healthcare Co's ROE % or its related term are showing as below:
SAU:4004'
s ROE % Range Over the Past 10 Years
Min: 7.96 Med: 14.13 Max: 18.39
Current: 11.34
During the past 13 years, Dallah Healthcare Co's highest ROE % was 18.39%. The lowest was 7.96%. And the median was 14.13%.
SAU:4004's ROE % is ranked better than 67.09% of 626
companies
in the Healthcare Providers & Services industry
Industry Median: 5.805
vs SAU:4004: 11.34
Dallah Healthcare Co (SAU:4004) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Dallah Healthcare Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's ROE % distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Dallah Healthcare Co (SAU:4004) has a ROE % of 8.26% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Dallah Healthcare Co and its competitors. This is 42% below median its historical median of 14.13. Over the past decade, Dallah Healthcare Co's ROE % has ranged from 7.96 to 18.39. According to the industry distribution chart, Dallah Healthcare Co ranks #206 out of 626 companies in the Healthcare Providers & Services industry, placing it in the top 32.9%.
Is Dallah Healthcare Co's ROE % too high?
Dallah Healthcare Co's current ROE % of 8.26% is 42% below median its 10-year median of 14.13. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 18.39. The Healthcare Providers & Services industry median ROE % is 5.81. Dallah Healthcare Co's value of 8.26% is 42.3% above this industry median. Based on the distribution chart, Dallah Healthcare Co ranks #206 out of 626 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dallah Healthcare Co has a GF Score™ of 91/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dallah Healthcare Co ranks #206 out of 626 companies for ROE %. This puts Dallah Healthcare Co in the upper half of its industry. The industry median ROE % is 5.81. Dallah Healthcare Co's value of 8.26% is 42.3% above this benchmark. Historically, Dallah Healthcare Co's own ROE % has ranged from 7.96 to 18.39 over the past decade. While the company's 10-year median is 14.13 vs. the industry median of 5.81, Dallah Healthcare Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.81, based on 626 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current ROE % of 8.26% is 42.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Dallah Healthcare Co and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current ROE % is 8.26%, which is 42% below median its own 10-year median of 14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼205.01, compared to a current price of ﷼109.80 — trading 46.4% below its estimated fair value. The current ROE % is 8.26%, which is 42% below median its 10-year median of 14.13 and 42.3% above the Healthcare Providers & Services industry median of 5.81. Dallah Healthcare Co's overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current ROE % is 8.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼109.80 is trading 46.4% below its estimated GF Value™ of ﷼205.01.
GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4004:
ROE %: 8.26% (42% below median its 10-year median of 14.13)
GF Value™: ﷼205.01 vs. price of ﷼109.80 (46.4% below fair value)
Industry Position: 42.3% above the Healthcare Providers & Services median (#206 of 626)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
91GF Score
Get the complete analysis for SAU:4004
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
